Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial

NCT01829295 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT01829295
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01829295 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial
Lead sponsor
University of California, San Francisco
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2013
Completion date
August 9, 2018
Enrollment
216 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

uveitis